Ambulatory microdose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease

Bradley M. Buchheit, Timothy Joslin, Helen N. Turner, Trisha E. Wong

Research output: Contribution to journalArticlepeer-review

Abstract

Sickle cell disease (SCD) is a hematologic disorder defined by presence of sickle-shaped red blood cells that can occlude blood vessels and cause tissue ischemia and pain. Treating SCD pain adequately and safely is difficult given today's opioid climate. Buprenorphine-naloxone has been described as an alternative option to treat chronic pain in the adult literature; however, it historically required discontinuation of full-agonist opioids before initiation, resulting in opioid withdrawal. Herein we present two adolescents with SCD who successfully weaned off large doses of full-agonist opioids by using microdose induction of buprenorphine-naloxone in clinic, without experiencing significant opioid withdrawal. Ambulatory microdose induction may remove hurdles that otherwise would discourage patients from trying this regimen while still controlling pain safely.

Original languageEnglish (US)
Article numbere28766
JournalPediatric Blood and Cancer
Volume68
Issue number1
DOIs
StatePublished - Jan 2021

Keywords

  • buprenorphine
  • opioid dependence
  • pain management
  • sickle cell disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Ambulatory microdose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease'. Together they form a unique fingerprint.

Cite this